Effect of a nitric oxide synthase inhibitor and a CXC chemokine receptor-4 antagonist on tumor growth and metastasis in a xenotransplanted mouse model of adenoid cystic carcinoma of the oral floor

Takaoka,Kazuki; Hidaka,Sayaka; Hashitani,Susumu; Segawa,Emi; Yamamura,Michiyo; Tanaka,Noriaki; Zushi,Yusuke; Noguchi,Kazuma; Kishimoto,Hiromitsu; Urade,Masahiro

doi:10.3892/ijo.2013.2011

Effect of a nitric oxide synthase inhibitor and a CXC chemokine receptor-4 antagonist on tumor growth and metastasis in a xenotransplanted mouse model of adenoid cystic carcinoma of the oral floor

Authors:
- Kazuki Takaoka
- Sayaka Hidaka
- Susumu Hashitani
- Emi Segawa
- Michiyo Yamamura
- Noriaki Tanaka
- Yusuke Zushi
- Kazuma Noguchi
- Hiromitsu Kishimoto
- Masahiro Urade
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan, The First Department of Oral and Maxillofacial Surgery, Osaka University Graduate School of Dentistry, Suita, Osaka, Japan
Published online on: July 8, 2013 https://doi.org/10.3892/ijo.2013.2011
Pages: 737-745

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nitric oxide (NO) is related to angiogenesis and tumor progression and chemokine receptor-4 (CXCR4) plays a central role in cell migration in metastasis and dissemination of cancer. The present study evaluated the effectiveness of a NOS inhibitor and a CXCR4 antagonist, given as single agents or in combination, in a xenotransplanted mouse model of adenoid cystic carcinoma (ACC) of the oral floor. A metastatic tumor (ACCIM) derived from a cervical metastatic lesion of human ACC that was transplantable in nude mice was used. ACCIM showed a high frequency of spontaneous metastasis to the lung when transplanted subcutaneously in nude mice. Mice with subcutaneous transplants of ACCIM were subdivided into six groups and intraperitoneally received one of the following treatments daily for 5 weeks: a) PBS (control), b) AMD3100 (CXCR4 antagonist), c) L-NAME (NOS inhibitor), d) 1400W (iNOS inhibitor), e) both AMD3100 and L-NAME (AMD3100+L-NAME) and f) both AMD3100 and 1400W (AMD3100+1400W). Tumor growth was evaluated during treatment and metastasis was assessed at 28 weeks. Single-agent treatment with AMD3100, L-NAME or 1400W inhibited tumor growth by 20.8, 26.5 and 54.5%, respectively. Combined treatment with AMD3100+L-NAME and AMD3100+1400W inhibited tumor growth remarkably by 48.0 and 50.2%, respectively. Immunohistochemical analysis revealed lower expression of CXCR4, iNOS and eNOS in tumor cells treated with AMD3100+L-NAME or AMD3100+1400W compared to control tumor cells and increased numbers of apoptotic tumor cells were demonstrated using the TUNEL method. CXCR4 expression decreased in 1400W-treated tumors using western blot analysis. When the effect of each agent on tumor-induced angiogenesis in tumor stroma was examined histologically, microvessel density was significantly lower in the groups treated with 1400W, AMD3100+L-NAME or AMD3100+1400W compared to the control, AMD3100 and L-NAME groups. Moreover, treatment with AMD3100 or 1400W markedly inhibited lung metastasis. Our results indicated that single-agent treatment with 1400W and combined treatment with AMD3100+L-NAME or AMD3100+1400W induced apoptosis and significantly inhibited tumor-induced angiogenesis and proliferation of ACCIM in vivo. Blockade of CXCR4 and iNOS was suggested to inhibit lung metastases from ACCIM. CXCR4 and iNOS may, thus, be important prognostic factors for long-term survival in ACC.

View Figures

View References

1	de Kerviler E, Bely N, Laccourreye O, Clement O, Halimi P and Frija G: The aryepiglottic fold as a rare location of adenoid cystic carcinoma. Am J Neuroradiol. 16:1375–1377. 1995.PubMed/NCBI
2	Fordice J, Kershaw C, El-Naggar A and Goepfert H: Adenoid cystic carcinoma of the head and neck. Predictors of morbidity and mortality. Arch Otolaryngol Head Neck Surg. 125:149–152. 1999. View Article : Google Scholar : PubMed/NCBI
3	Nathan C and Xie QW: Nitric oxide synthases: roles, tolls and controls. Cell. 78:915–918. 1994. View Article : Google Scholar : PubMed/NCBI
4	Fukumura D, Kashiwagi S and Jain RK: The role of nitric oxide in tumor progression. Nat Rev Cancer. 6:521–534. 2006. View Article : Google Scholar : PubMed/NCBI
5	Beckman JS, Beckman YW, Chen J, Marshall PA and Freeman BA: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric and superoxide. Proc Natl Acad Sci USA. 87:1620–1624. 1990. View Article : Google Scholar : PubMed/NCBI
6	Prueitt RL, Boersma BJ, Howe TM, et al: Inflammation and IGF-1 activate the Akt pathway in breast cancer. Int J Cancer. 120:796–805. 2007. View Article : Google Scholar : PubMed/NCBI
7	Ekmekcioglu S, Ellerhorst J, Prieto VG, et al: Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer. 119:861–866. 2006. View Article : Google Scholar : PubMed/NCBI
8	Ying L and Hofseth LJ: An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res. 67:1407–1410. 2007. View Article : Google Scholar : PubMed/NCBI
9	Ohtsu N, Takaoka K, Segawa E, et al: Antitumor effect of inhibitors of nitric oxide synthase or cyclooxygenase-2 on human KB carcinoma cells overexpressing COX-2. Oncol Rep. 24:31–36. 2010.PubMed/NCBI
10	Muller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50–56. 2001. View Article : Google Scholar : PubMed/NCBI
11	Pablos JL, Amara A, Bouloc A, et al: Stromal-cell derived factor is expressed by dendritic cells and endothelium in human skin. Am J Pathol. 155:1577–1586. 1999. View Article : Google Scholar : PubMed/NCBI
12	Aiuti A, Webb IJ, Bleul C, Springer T and Gutierrez-Ramos JC: The chemokine SDF-1 is a chemoattractant for human CD34⁺ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34⁺ progenitors to peripheral blood. J Exp Med. 185:111–120. 1997.PubMed/NCBI
13	Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T and Honjo T: Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science. 261:600–603. 1999. View Article : Google Scholar : PubMed/NCBI
14	Bleul CC, Fuhlbrigge RC, Cassasnovas JM, Aiuti A and Springer TA: A high efficacious lymphocyte chemoattractant, stromal cell-derived factor-1α (SDF-1α). J Exp Med. 184:1101–1109. 1996.
15	Campbell JJ, Hedrick J, Zlotnik A, Siani MA, Thompson DA and Butcher EC: Chemokines and the arrest of lymphocytes rolling under flow conditions. Science. 279:381–384. 1998. View Article : Google Scholar : PubMed/NCBI
16	Grabovsky V, Feigelson S, Chen C, et al: Subsecond induction of α4 integrin clustering by immobilized chemokines stimulates leukocyte tethering and rolling on endothelial vascular cell adhesion molecule 1 under flow conditions. J Exp Med. 192:495–506. 2000.
17	Wright N, Hidalgo A, Rodriguez-Frade JM, et al: The chemokine stromal cell-derived factor-1α modulates α4β7 integrin-mediated lymphocytes adhesion to mucosal addressin cell adhesion molecule-1 and fibronectin. J Immunol. 168:5268–5277. 2002.
18	Ganju RK, Brubaker SA, Meyer J, et al: The α-chemokine, stromal cell-derived factor-1α, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. J Biol Chem. 273:23169–23175. 1998.
19	Homey B, Muller A and Zlotnik A: Chemokines: agents for the immunotherapy of cancer? Nat Rev Immunol. 2:175–184. 2002. View Article : Google Scholar : PubMed/NCBI
20	Cardones AR, Murakami T and Hwang ST: CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via β(1) integrin. Cancer Res. 63:6751–6757. 2003.PubMed/NCBI
21	Murakami T, Maki W, Cardones AR, et al: Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 62:7328–7234. 2002.PubMed/NCBI
22	Robledo MM, Bartolome RA, Longo N, et al: Expression of functional chemokine receptor CXCR3 and CXCR4 on human melanona cells. J Biol Chem. 276:45098–45105. 2001. View Article : Google Scholar : PubMed/NCBI
23	Zushi Y, Noguchi K, Hashitani S, et al: Relations among expression of CXCR4, histological patterns and metastatic potential in adenoid cystic carcinoma of head and neck. Int J Oncol. 33:1133–1139. 2008.PubMed/NCBI
24	Hashitani S, Urade M, Zushi Y, Segawa E, Okui S and Sakurai K: Establishment of nude mouse transplantable model of a human adenoid cystic carcinoma of the oral floor showing metastasis to the lymph node and lung. Oncol Rep. 17:67–72. 2007.PubMed/NCBI
25	Ovejera AA, Houchens DP and Baker AD: Chemotherapy of human tumor xenografts in genetically athymic mice. Ann Clin Lab Sci. 8:50–56. 1978.PubMed/NCBI
26	Hsu SM, Raine L and Franger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 29:577–580. 1981. View Article : Google Scholar : PubMed/NCBI
27	Gavrieli Y, Sherman Y and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 119:493–501. 1992. View Article : Google Scholar : PubMed/NCBI
28	Ekmekcioglu S, Tang C and Grimm EA: NO news is not necessarily good news in cancer. Curr Cancer Drug Targets. 5:103–115. 2005. View Article : Google Scholar
29	Wink DA, Ridnour LA, Hussain SP and Harris CC: The reemergence of nitric oxide and cancer. Nitric Oxide. 19:65–67. 2008. View Article : Google Scholar : PubMed/NCBI
30	Li G, Yang T and Yan J: Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun. 299:886–890. 2002. View Article : Google Scholar : PubMed/NCBI
31	Engels K, Knauer SK, Loibl S, et al: NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res. 68:5159–5166. 2008. View Article : Google Scholar : PubMed/NCBI
32	Fetz V, Bier C, Habtemichael N, et al: Inducible NO synthase confers chemoresistance in head and neck cancer by modulating survivin. Int J Cancer. 124:2033–2041. 2009. View Article : Google Scholar : PubMed/NCBI
33	Roy HK, Wali RK, Kim Y, et al: Inducible nitric oxide synthase (iNOS) mediates the early increase of blood supply (EIBS) in colon carcinogenesis. FEBS Lett. 581:3857–3862. 2007. View Article : Google Scholar : PubMed/NCBI
34	Singh RP and Agarwal R: Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents. Curr Cancer Drug Targets. 7:475–483. 2007. View Article : Google Scholar : PubMed/NCBI
35	Nguyen DX, Bos PD and Massague J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
36	Joyce JA and Pollard JW: Microenvironmental regulation of metastasis. Nat Rev Cancer. 9:239–252. 2009. View Article : Google Scholar : PubMed/NCBI
37	Yasuoka H, Kodama R, Hirokawa M, et al: CXCR4 expression in papillary thyroid carcinoma: induction by nitric oxide and correlation with lymph node metastasis. BMC Cancer. 8:2742008. View Article : Google Scholar : PubMed/NCBI
38	Yasuoka H, Tsujimoto M, Yoshidome K, et al: Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis. BMC Cancer. 8:3402008. View Article : Google Scholar : PubMed/NCBI